Landmark editorial denounces 'poor publication practices' in spine research

The unusually blunt editorial in The Spine Journal notes that in 13 trials involving 780 patients, industry-funded researchers did not report a single adverse advent involving Medtronic's Infuse Bone Graft. (The product, approved for certain spinal-fusion surgeries, is designed to eliminate the need to harvest bone from the hip.)

The editorial in the nation's leading spine journal notes that the authors of nearly all the trials had financial ties with the manufacturer, with investigators earning as much as $26 million per study.

However, subsequent studies have documented serious adverse events, including inflammatory reactions, cancer, infection and implant dislodgement.

Flawed clinical research of the bone growth product and inadequate dislcosure of industry relationships are examples of the problems arising from financial ties between physicians and the medical device and pharmaceutical industries.

"We find ourselves at a precarious intersection of professionalism, morality and public safety," the editorial states. "We work under a burden of suspicion that new technology research and publication is simply a 'broken system' as currently practiced. Our professionalism... is fundamentally challenged by the threat of 'tainted science.'"

The editorial goes on: "It harms patients to have biased and corrupted research published. It harms patients to have unaccountable special interests permeate medical research. It harms patients when poor publication practices become business as usual."

Researchers who have financial ties to industry often say they have too much integrity to allow industry funding to affect their objectivity. The editorial says this "choirboy defense" lacks even minimum credibility.

"Instead the press and public assume that multimillion-dollar compensation packages can and do alter the balance of objectivity."

Provided by Loyola University Health System